Find Clinical Trial

Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period. An international multicentre, 3 parallel groups, randomised, double blind, placebo-controlled phase II study.


← Back
Study Phase

Phase 2

Therapeutic Area

Neuropsychiatric Diseases

IndicationMild Cognitive Impairment
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

S018986

Active Substance CodeS018986
Protocol CodeCL2-18986-009
EudraCT Code2004-004327-35
NCT CodeNCT00202540


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility